|
Characteristics
|
All patients (n = 134)
|
CD16+ after therapy (n = 65, 48.51%)
|
CD16low/− after therapy (n = 69, 51.49%)
|
P value
|
|---|
|
n
|
%
|
n
|
%
|
n
|
%
|
|---|
|
Age (years)
|
|
<65
|
70
|
52.24%
|
36
|
51.43%
|
34
|
48.57%
|
0.479
|
|
≥65
|
64
|
47.76%
|
29
|
45.31%
|
35
|
54.69%
| |
|
Gender
|
|
Male
|
82
|
61.19%
|
42
|
51.22%
|
40
|
48.78%
|
0.43
|
|
Female
|
52
|
38.81%
|
23
|
44.23%
|
29
|
55.77%
| |
|
Tumor location
|
|
Rectum
|
68
|
50.75%
|
32
|
47.06%
|
36
|
52.94%
|
0.733
|
|
Colon
|
66
|
49.25%
|
33
|
50.00%
|
33
|
50.00%
| |
|
Tumor Size
|
|
≥5 cm
|
57
|
42.54%
|
25
|
43.86%
|
32
|
56.14%
|
0.354
|
|
<5 cm
|
77
|
57.46%
|
40
|
51.95%
|
37
|
48.05%
| |
|
CEA level after therapy
|
|
≤5 ng/ml
|
114
|
85.07%
|
60
|
52.63%
|
54
|
47.37%
|
0.023
|
|
>5 ng/ml
|
20
|
14.93%
|
5
|
25.00%
|
15
|
75.00%
| |
|
CA199 level after therapy
|
|
≤27 ng/ml
|
116
|
86.57%
|
61
|
52.59%
|
55
|
47.41%
|
0.016
|
|
>27 ng/ml
|
18
|
13.43%
|
4
|
22.22%
|
14
|
77.78%
| |
|
TNM stage (AJCC)
|
|
Stage II
|
98
|
73.13%
|
45
|
45.92%
|
53
|
54.08%
|
0.322
|
|
Stage III
|
36
|
26.87%
|
20
|
55.56%
|
16
|
44.44%
| |
|
Location of recurrence
|
|
Loco-regional
|
3
|
13.04%
|
2
|
40.00%
|
1
|
5.56%
|
0.042
|
|
liver + lung
|
3
|
13.04%
|
2
|
40.00%
|
1
|
5.56%
| |
|
liver
|
10
|
43.48%
|
1
|
20.00%
|
9
|
50.00%
| |
|
lung
|
6
|
26.09%
|
0
|
0.00%
|
6
|
33.33%
| |
|
peritoneum
|
1
|
4.35%
|
0
|
0.00%
|
1
|
5.56%
| |
